Oxybutynin in primary hyperhidrosis: A long‐term real‐life study

Hyperhidrosis is a condition of excessive sweating beyond physiological parameters that can seriously impair quality of life. This study aims to evaluate the oral oxybutynin effectiveness in hyperhidrosis, besides its tolerance and safety. In a real‐life long‐term study, 30 patients with primary hyp...

Full description

Saved in:
Bibliographic Details
Published inDermatologic therapy Vol. 33; no. 6; pp. e14344 - n/a
Main Authors Almeida, Ada Regina Trindade, Ferrari, Fernanda, Restrepo, Maria Victoria Suarez, Rocha, Vanessa Barreto
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.11.2020
Subjects
Adolescent
Adult
Aged
Child
Female
HDSS
Humans
hyperhidrosis
Hyperhidrosis - diagnosis
Hyperhidrosis - drug therapy
Longitudinal Studies
Male
Mandelic Acids - adverse effects
Middle Aged
oxybutynin
pharmacology
Quality of Life
therapy‐systemic
Treatment Outcome
Young Adult
hyperhidrosis
oxybutynin
therapy-systemic
quality of life
HDSS
pharmacology
Online AccessGet full text

Cover

More Information
Summary:Hyperhidrosis is a condition of excessive sweating beyond physiological parameters that can seriously impair quality of life. This study aims to evaluate the oral oxybutynin effectiveness in hyperhidrosis, besides its tolerance and safety. In a real‐life long‐term study, 30 patients with primary hyperhidrosis and Hyperhidrosis Disease Severity Scale (HDSS) with score of at least two were submitted to a questionnaire to assess demographic data, HDSS and side effects of oxybutynin. Most patients were women (n = 23, 76.7%), median age was 40 years (range 12‐70, SD 17.5) and 17(56.7%) had family history of hyperhidrosis. The most common hyperhidrosis form was axillary (n = 15, 50.0%), followed by palmoplantar (n = 8, 26.7%), cranio‐facial (n = 11, 36.7%) and trunk (n = 5, 16.7%). Median duration of treatment was 2.4 years (range 1‐6 years, SD 1.3). Thus, all patients used oxybutynin for at least 1 year, 30% for 2 years, 20% 3 years, 17% 4 years, and 3% 6 years. There was a significant improvement in HDSS score of patients (P < .001). This real life study suggests that oxybutynin is effective and safe for treatment of hyperhidrosis, both in children and adults, with mild and tolerable side effects, with significant improvement in HDSS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1396-0296
1529-8019
DOI:10.1111/dth.14344